Silence the Shame, is set to host a college empowerment summit to provide resources, support and inspiration to college ...

Kevin Gao, President of Huawei Cloud Public Cloud Business, presented a keynote speech " One Step to Intelligence, One Leap ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Flashpoint Therapeutics proudly announces that its scientific founder, Professor Chad A. Mirkin, has been awarded the 2024 Kavli Prize in Nanoscience for his pioneering work on spherical nucleic acids ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Applied Therapeutics (APLT – Research Report) yesterday and set a price target ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Why the Gut Microbiome is Critical to Children’s Health: Harnessing Microbiome Science to End Malnutrition” is a seminal ...